Estrone sulfate
 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| Pharmacokinetic data | |
| Biological half-life | 12 hours[2] |
| Identifiers | |
| |
| CAS Number |
481-97-0  438-67-5 (sodium) 7280-37-7 (piperazine) |
| PubChem (CID) | 3001028 |
| IUPHAR/BPS | 4749 |
| DrugBank |
DB04574 |
| ChemSpider |
2272513 |
| UNII |
QTL48N278K |
| ChEBI |
CHEBI:17474 |
| ChEMBL |
CHEMBL494753 |
| Chemical and physical data | |
| Formula | C18H22O5S |
| Molar mass | 350.43 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Estrone sulfate (E1S), or 17β-estrone 3-sulfate, is a natural, endogenous steroid and an estrogen ester.[3] E1S itself is biologically inactive, with less than 1% of the relative binding affinity of estradiol for the ERα and ERβ,[4] but it can be converted by steroid sulfatase (also called estrogen sulfatase) into estrone, which is an estrogen.[5] Simultaneously, estrogen sulfotransferases convert estrone to E1S, resulting in an equilibrium between the two steroids in various tissues.[5] E1S is thought to serve as a long-lasting reservoir for estrone and estradiol in the body.[6][7] In addition to its biological role, as the sodium salt, sodium estrone sulfate, E1S is the primary active estrogen in conjugated equine estrogens (Premarin) and esterified estrogens.[1] Aside from its presence in these estrogen formulations, E2S is not available as a commercial pharmaceutical drug. However, it is available as estropipate (piperazine estrone sulfate), a salt of E1S and piperazine.[1]
See also
- Estradiol sulfate
- Estriol glucuronide
- DHEA sulfate
- Pregnenolone sulfate
- Lipoidal estradiol
- Catechol estrogen
References
- 1 2 3 Mary C. Brucker; Tekoa L. King (8 September 2015). Pharmacology for Women’s Health. Jones & Bartlett Publishers. pp. 361–. ISBN 978-1-284-05748-5.
- ↑ Lynn Wecker; Stephanie Watts; Carl Faingold; George Dunaway; Lynn Crespo (1 April 2009). Brody's Human Pharmacology. Elsevier Health Sciences. pp. 456–. ISBN 0-323-07575-4.
- ↑ Rogerio A. Lobo (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 768–. ISBN 978-0-08-055309-2.
- ↑ Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.
- 1 2 Tommaso Falcone; William W. Hurd (22 May 2013). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 5–6. ISBN 978-1-4614-6837-0.
- ↑ Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (11 November 2015). Williams Textbook of Endocrinology (13th ed.). Elsevier Health Sciences. pp. 607–. ISBN 978-0-323-34157-8.
- ↑ James M. Greenblatt; Kelly Brogan (27 April 2016). Integrative Therapies for Depression: Redefining Models for Assessment, Treatment and Prevention. CRC Press. pp. 198–. ISBN 978-1-4987-0230-0.